Retrospective Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 7, 2023; 29(29): 4580-4592
Published online Aug 7, 2023. doi: 10.3748/wjg.v29.i29.4580
Prevalence and risk factors of osteoporosis detected by dual-energy X-ray absorptiometry among Chinese patients with primary biliary cholangitis
Jia-Liang Chen, Yao Liu, Yu-Fei Bi, Xian-Bo Wang
Jia-Liang Chen, Yao Liu, Yu-Fei Bi, Xian-Bo Wang, Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
Author contributions: Chen JL and Wang XB designed the research; Chen JL, Liu Y and Bi YF performed the research; Chen JL and Liu Y analyzed the data; Chen JL wrote the manuscript; Wang XB supervised the report; all authors reviewed and approved the final manuscript.
Supported by Capital’s Funds for Health Improvement and Research, No. CFH2018-1-2172; and Beijing Ditan Hospital Scientific Research Fund Project, No. DTYM202102.
Institutional review board statement: The study was approved by the Institutional Ethical Review Board of Beijing Ditan Hospital, No. DTEC-KT2022-010-01.
Informed consent statement: As this study used anonymous and pre-existing data, the requirement for the informed consent from patients was waived.
Conflict-of-interest statement: We have no financial relationships to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xian-Bo Wang, MD, PhD, Chief Physician, Professor, Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Beijing 100015, China. wangxb@ccmu.edu.cn
Received: June 7, 2023
Peer-review started: June 7, 2023
First decision: June 16, 2023
Revised: June 21, 2023
Accepted: July 19, 2023
Article in press: July 19, 2023
Published online: August 7, 2023
ARTICLE HIGHLIGHTS
Research background

Primary biliary cholangitis (PBC) is a chronic immune-mediated, progressive cholestatic liver disease. Osteoporosis is an extrahepatic complication of PBC that increases the risk of fractures and mortality.

Research motivation

Although the prevalence of osteoporosis in PBC is high in Europe and North America, relevant epidemiological studies of osteoporosis in patients with PBC in China and the Asia-Pacific region is lack.

Research objectives

To assess the prevalence and clinical characteristics of osteoporosis in Chinese patients with PBC.

Research methods

We performed a retrospective observational study to evaluation the prevalence and risk factors of osteoporosis in Chinese patients with PBC from a tertiary care center who underwent bone mineral density (BMD) assessment using dual-energy X-ray absorptiometry between January 2013 and December 2021. Demographic, serological, clinical, and histological data were collected. Independent risk factors for osteoporosis were identified by multivariate logistic regression analysis.

Research results

The prevalence of osteoporosis in Chinese patients with PBC was 45.5%. Osteoporosis in PBC is strongly associated with older age, lower body mass index (BMI), previous steroid use, the severity of liver disease, and advanced histological stage.

Research conclusions

Osteoporosis is very common in Chinese patients with PBC, allowing for prior screening of BMD in those PBC patients with older age, lower BMI, previous steroid therapy, and advanced liver disease.

Research perspectives

This study provides reference information for future PBC-related guideline development and public policy formulation in China and the Asia-Pacific region.